<DOC>
	<DOC>NCT01254422</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia. Primary Objectives: - To describe the safety (in terms of solicited and unsolicited adverse events) of the CYD dengue vaccine in all subjects after each dose. - To describe the antibody response to each dengue virus serotype post-Dose 2 and post-Dose 3</brief_summary>
	<brief_title>Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia</brief_title>
	<detailed_description>Healthy participants aged 2 to 11 years will receive 3 vaccinations at pre-determined schedules and will be followed-up for at least 6 months after the last vaccination.</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 to 11 years on the day of inclusion Assent form has been signed and dated by the subject (for subjects â‰¥ 7 years) and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative, and by an independent witness if the two parents or legally acceptable representative are illiterate Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures Subject in good health, based on medical history and physical examination For a female subject of childbearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination Known pregnancy, or a positive urine pregnancy test (for female subject of childbearing potential only) Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Planned receipt of any vaccine in the 4 weeks following the trial first vaccination, except for pandemic influenza vaccination receipt of blood or bloodderived products in the past 3 months, which might interfere with assessment of the immune response Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months; or longterm systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) Seropositivity for human immunodeficiency virus (HIV) reported by the parent/legally acceptable representative Known systemic hypersensitivity to any of the vaccine components, or history of a lifethreatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion Subjects who plan to move to another country/region within the 18 coming months Identified as a child (adopted or natural) of the Investigator or of site employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>CYD dengue vaccine</keyword>
</DOC>